Search results
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 24 hours agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 16 hours agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 14 hours agoSales of human papillomavirus vaccine Gardasil jumped 14% to $2.25 billion. That narrowly topped...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 24 hours agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 18 hours agoIn Diabetes, Januvia/Janumet (diabetes) franchise sales declined 21% year over year to $670 million....
20 Fastest Growing Health Tech Companies in the World
Insider Monkey via Yahoo Finance· 19 hours agoIn this article, we will be taking a look at the 20 fastest growing health tech companies in the...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 2 days agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...
How Many More Ozempic-like Drugs Are In the Pipeline — Here’s What Researchers Are Working On
Inverse· 6 days agoFew drugs have achieved the stardom that semaglutide, marketed in the United States as Ozempic or...
Q3 2024 Earnings Forecast for Merck & Co., Inc. Issued By Leerink Partnrs (NYSE:MRK)
ETF DAILY NEWS· 4 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2024 earnings per share estimates for Merck & Co., Inc. in a report released on Friday, April ...
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $131.25
ETF DAILY NEWS· 4 days agoMerck & Co., Inc. (NYSE:MRK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat reports ...